Lauren Toms
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lauren Toms has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ari Waisman
Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz
1 shared publication Athina Papaemmanouil
Faculty of Biology, Medicine and Health, University of Manchester, M13 9PT Manchester, UK
1 shared publicationBernadett Martinecz
Momentum" Laboratory of Neuroimmunology, Institute of Experimental Medicine, Szigony u. 43, 1083 Budapest, Hungary
1 shared publicationDenis G. Alferez
Breast Biology Group, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester
1 shared publicationEmily P. Offer
Medicines Discovery Catapult, Block 35, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4ZF
1 shared publication- Emmanuel Pinteaux
Division of Neuroscience, Faculty of Biology, Medicine, and Health, School of Biological Sciences, University of Manchester, Manchester M13 9PL, UK
1 shared publication
Latest Publications
- Open Access
Grading HER2 at the nanoscale in clinical tissue
To guide diagnosis and treatment, breast cancer biopsies are assessed for HER2 status and assigned one of four grades (0-3+). While current practices are sufficient for detection of HER2 overexpression (3+), there is a need for more sensitive methods capable of characterising lower HER2 expression in patients who may still benefit from HER2-targeted therapies. Super-resolution fluorescence microscopy techniques, such as single molecule localisation microscopy (SMLM), have reshaped the study of nanoscale molecular architecture by visualising single target molecules in a range of sample types. Here, we have developed a quantitative SMLM workflow to visualise HER2 nanoclustering in patient-derived xenografts (PDX) and clinical breast tumour tissue from eight patients spanning all disease grades. Analysis of HER2 cluster architecture revealed grade-dependent changes in size of cluster and HER2 abundance. We then applied a blinded data-driven approach to regroup samples based on this nanoscale HER2 clustering. This led to the reclassification of three samples into new groups, due to similarities in nanoscale signature. Together, these findings demonstrate that quantitative fluorescence nanoscopy can be used to identify clinical HER2 phenotypes across a range of expression levels due to its exquisite sensitivity, and this could be leveraged to stratify patients for targeted therapy.
Open AccessGrading HER2 at the nanoscale in clinical tissue
To guide diagnosis and treatment, breast cancer biopsies are assessed for HER2 status and assigned one of four grades (0-3+). While current practices are sufficient for detection of HER2 overexpression (3+), there is a need for more sensitive methods capable of characterising lower HER2 expression in patients who may still benefit from HER2-targeted therapies. Super-resolution fluorescence microscopy techniques, such as single molecule localisation microscopy (SMLM), have reshaped the study of nanoscale molecular architecture by visualising single target molecules in a range of sample types. Here, we have developed a quantitative SMLM workflow to visualise HER2 nanoclustering in patient-derived xenografts (PDX) and clinical breast tumour tissue from eight patients spanning all disease grades. Analysis of HER2 cluster architecture revealed grade-dependent changes in size of cluster and HER2 abundance. We then applied a blinded data-driven approach to regroup samples based on this nanoscale HER2 clustering. This led to the reclassification of three samples into new groups, due to similarities in nanoscale signature. Together, these findings demonstrate that quantitative fluorescence nanoscopy can be used to identify clinical HER2 phenotypes across a range of expression levels due to its exquisite sensitivity, and this could be leveraged to stratify patients for targeted therapy.
- Open Access
- 15 January 2025
- Published by Elsevier in SLAS Discovery
- Vol. 31, 100209
Super-resolution microscopy as a drug discovery tool
- 15 January 2025
- Published by Elsevier in SLAS Discovery
- Vol. 31, 100209
Open AccessSuper-resolution microscopy as a drug discovery tool
- Open Access
- 1 February 2019
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 76, 126-138
Interleukin-1 mediates ischaemic brain injury via distinct actions on endothelial cells and cholinergic neurons
- 1 February 2019
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 76, 126-138
Open AccessInterleukin-1 mediates ischaemic brain injury via distinct actions on endothelial cells and cholinergic neurons